Abstract
A new 3-hydroxypyridine derivative, 2-ethyl-6-methyl-3-hydroxypyridine N-acetyl-L-glutamate (EMOP-AG) has been synthesized. It is established that EMOP-AG (10 and 30 mg/kg, single administration) exhibits antihypoxic activity on various models of acute hypoxia (baric hypoxia with hypercapnia, hemic and hystotoxic hypoxia) in mice and produces equal or stronger effect in comparison to referece drugs (amtizol, mexidol, and emoxipin). In addition, EMOP-AG (10 and 30 mg/kg per day) has a marked neuroprotective effect in rats with bilateral ligation of common carotid arteries and is more effective in the treatment of neurologic deficiency than amtizol (10 and 30 mg/kg per day), mexidol (90 and 120)mg/kg per day) and emoxipin (120 mg/kg per day). It is also established that EMOP-AG (30 mg/kg) can prevent amnesia in a step-down passive avoidance situation caused by different factors (maximal electroshock, scopolamine, acute hypoxia in hermetic chamber, and combined action of extremal factors).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
